Dec 11, 2023 07:30PM Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

Nov 14, 2023 07:00AM 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Sep 12, 2023 06:55AM 2seventy bio (TSVT) and JW Therapeutics To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies

Sep 12, 2023 06:55AM 2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies

Jun 14, 2023 07:02AM 2seventy bio (TSVT) Announces Clinical Study Pause of PLAT-08 Trial

Jun 14, 2023 07:00AM 2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

May 19, 2023 06:01AM 2seventy bio (TSVT) Presents Late-Breaking Results for SC-DARIC33

May 19, 2023 06:00AM 2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

May 11, 2023 12:37PM 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Apr 17, 2023 07:09AM Bristol-Myers (BMY), 2seventy (TSVT) Announces Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed R/R Multiple Myeloma

Apr 17, 2023 06:59AM Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma

Feb 10, 2023 11:15AM Bristol-Myers (BMY), 2seventy (TSVT) Announces Abecma Reduced Risk of Disease Progression, Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for R/R Multiple Myeloma Based on Results f

Feb 10, 2023 11:13AM Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Resul

Jan 18, 2023 11:35AM Medigene Receives $3 Million Milestone Payment from 2seventy bio

Nov 3, 2022 09:06AM 2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Oct 27, 2022 07:00AM 2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

Sep 7, 2022 07:04AM 2seventy bio (TSVT) Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients

Sep 7, 2022 07:00AM 2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients

Aug 10, 2022 06:47AM Bristol-Myers Squibb (BMY) and 2seventy (TSVT) Report Positive Topline Results from KarMMa-3 Trial

Aug 10, 2022 06:45AM Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in

Mar 22, 2022 07:00AM 2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress

Feb 14, 2022 07:30AM 2seventy bio Announces Key Management Appointments